Mr. Richard John Flynn, MD Psychiatry & Neurology - Neurology Medicare: Not Enrolled in Medicare Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-888-5858 Fax: 570-882-3023 |
Carlos Ynigo Dy Lopez, M.D. Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-887-2838 Fax: 570-887-3192 |
Charles R Mcgurk, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-888-6666 Fax: 570-882-4379 |
Anthony L Nicotera, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-888-6666 Fax: 570-882-4379 |
Dr. Paul Edward Buckthal, MD Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-888-5858 |
Dr. Han Suk Koh, MD Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-888-5858 |
Monique Elise Simpson, M.D. Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-888-6666 |
Mitchell Felder, Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-882-3090 |
Joita Nedelcu, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-888-6666 Fax: 570-882-4379 |
News Archive
Agenus Inc., announced final results from a single-arm, multi-institutional, open-label, Phase 2 study showing that patients with newly diagnosed glioblastoma multiforme (GBM) who received Agenus' Prophage autologous cancer vaccine added to the standard of care treatment, lived nearly twice as long as expected.
Bionor Immuno today announced that it has advanced its efforts to develop the first HIV therapeutic immunization with the dosing of patients in a global Phase 2b clinical trial of the company's lead candidate (Vacc-4x).
Scientists at the Naval Research Laboratory (NRL) recently reported the detection of toxins with unprecedented speed, sensitivity, and simplicity.
New research has revealed new insights into common asthma aerosol treatments to aid the drug's future improvements which could benefit hundreds of millions of global sufferers.
› Verified 4 days ago